MSB has shown efficacy in spades. CLBP will be the first " big one " for them.
I still think CHF will be seriously considered by the FDA for an AA for high-risk HFrEF patients with diabetes and/or myocardial ischemia so it could be the first of the two blockbusters ..... who knows but the FDA were the ones that requested the submission of additional information back in 2021, which was prepared and submitted by Mesoblast in 2022 .... now all that remains is the formal CHF meeting
2023 The Final Countdown, page-643
-
- There are more pages in this discussion • 2,761 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.010(1.09%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 94.0¢ | 89.5¢ | $4.970M | 5.436M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18877 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 6795 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |